Indian drug manufacturer Ranbaxy is contesting us multinational Pfizer in 17 countries. It is filing for the right to manufacture generic versions of the world's bestselling drug Lipitor and a combination drug Caduet, in the us. But it hasn't really struck a blow for the generic pharma industry: Ranbaxy remains a supporter of product patents and incremental innovations at home.
At the crux of the dispute is Pfizer's designs on a patent extension by combining Lipitor with another drug: Norvasc. Ranbaxy senses a weakness in Pfizer's case and is questioning the us multinational's rights in several countries. It has also filed applications to market, and make generic versions of Caduet. Pfizer is contesting these applications (See box: Items of contest).Shamnad Basheer of George Washington University Law School, however, believes that the Caduet patent will be invalidated since it does not really represent any "inventiveness". "The litigation can have a bearing on the Novartis dispute in India on the generic blood cancer drug, Gleevec," he said. (see 'Patent Puzzle', Down To Earth, February 28, 2007). Basheer believes that Caduet will not be patentable if it's a sum of the properties of Lipitor and Norvasc. "But Lipitor's patent has to end for a generic to come out," he notes.
Ranbaxy's spokespersons affirm this. They told Down To Earth, "We have a strategy to use r&d capabilities for generics andlitigate against patents which we consider weak. We are committed to developing drugs, affordable to all. We respect patents but when non-infringing products are developed such efforts must be rewarded.
Ranbaxy, in fact, is the only company whose comments feature in the Mashelkar committee report, pointing to a trend of lobby-savvy Indian pharma majors getting their view across.
We are a voice to you; you have been a support to us. Together we build journalism that is independent, credible and fearless. You can further help us by making a donation. This will mean a lot for our ability to bring you news, perspectives and analysis from the ground so that we can make change together.
Comments are moderated and will be published only after the site moderator’s approval. Please use a genuine email ID and provide your name. Selected comments may also be used in the ‘Letters’ section of the Down To Earth print edition.